Zoth Lota S.
SEC-identified person · CIK 1278219 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Engene Therapeutics Inc. ENGN | Director | filed 2023–2026 |
| Inovio Pharmaceuticals, INC. ino | Director | filed 2019–2026 |
| First Financial Bankshares INC ffin | Director | filed 2026–2026 |
| 89bio, Inc. ETNB | Director | filed 2020–2025 |
| Newlink Genetics Corp [NLNK] | Director | filed 2012–2024 |
| Zymeworks Inc. ZYME | Director | filed 2022–2022 |
| Zymeworks Inc. ZYME | Director | filed 2019–2021 |
| Spark Therapeutics, Inc. ONCE | Director · CHIEF SCIENTIFIC OFFICER | filed 2016–2019 |
| Orexigen Therapeutics, Inc. OREXQ | Director | filed 2012–2017 |
| Hyperion Therapeutics INC HPTX | Director | filed 2012–2015 |
| Medimmune INC /DE MEDI | Senior Vice President & CFO | filed 2006–2007 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.